Division of Nuclear Medicine
The Division of Nuclear Medicine, part of NYU Langone Health’s Department of Radiology, offers broad-spectrum molecular imaging services, as well as nuclear radiotherapy for thyroid cancers, bone cancers, and endocrine cancers and other conditions at locations in New York City and on Long Island.
We use the most up-to-date standardized imaging protocols and the latest radiopharmaceuticals and imaging equipment to interpret images, offer clinical consultations, and tailor radiotherapy protocols.
Under the leadership of Kent P. Friedman, MD, chief of nuclear medicine, our faculty educates future leaders in the field of nuclear medicine and collaborates on the latest imaging, therapy, and research protocols with other experts in the field. Resources available to our team include a radiochemistry facility, cyclotron laboratory, and the services of a dedicated PET/MRI imaging team.
Nuclear Medicine Education
Physicians who participate in radiology residencies at NYU Langone receive training in the fundamentals of nuclear medicine. Graduates qualify to supervise and interpret nuclear medicine imaging studies and are certified to perform therapies for hyperthyroidism, thyroid cancer, and liver cancer. Additional training is available for residents to become certified nuclear radiologists.
Medical students who have an interest in radiology and nuclear medicine can develop skills in nuclear imaging and nuclear therapies during the radiology selective and nuclear medicine elective as part of NYU Grossman School of Medicine’s MD curriculum.
Nuclear Medicine Research
Our faculty perform research on molecular imaging and nuclear radiotherapies. We are collaborating with the Division of Neuroradiology on a clinical trial to study the use of 177Lutetium-DOTATATE in patients with recurrent, unresectable meningiomas. We are also investigating expanded applications for 18F-fluciclovine (Axumin®) PET/MRI in patients with known and suspected prostate cancer. Other research areas of interest include the use of PET/MRI scans and novel radiopharmaceuticals to improve our understanding of the pathophysiology of dementia syndromes, head and neck cancers, and epilepsy.
Nuclear Medicine Clinical Services
The Division of Nuclear Medicine employs fellowship-trained physicians with expertise in the performance and interpretation of PET/CT and PET/MRI to evaluate different types of cancer, tumors, and blood disorders; brain and nervous system disorders; inflammatory diseases; and heart and vascular conditions.
We provide advanced radiotherapy for thyroid, bone, and endocrine cancers at Perlmutter Cancer Center locations in Manhattan, Brooklyn, and Long Island. These services include comprehensive thyroid cancer imaging, advanced dose calculation techniques, and radioiodine (I-131) treatments for thyroid cancer and hyperthyroidism, as well as radium-223 (Xofigo®) treatment for skeletal metastases. Treatment for neuroendocrine cancers with 177Lutetium-DOTATATE (Lutathera®) is available at NYU Langone’s Tisch Hospital.
We also offer general nuclear medicine imaging services—including PET/CT, PET/MRI, single-photon emission computerized tomography (SPECT), and SPECT/CT—at Tisch Hospital, NYU Langone Hospital—Brooklyn, NYU Langone Hospital—Long Island, and NYU Langone Radiology—Center for Biomedical Imaging, as well as at our many ambulatory practices in New York City and on Long Island.
A full range of nuclear medicine imaging services is available at the majority of our locations. Non-imaging studies, including blood volume analysis and renal function testing, are available at Tisch Hospital.